Return to search

Frazier taps Topper as senior advisor

Frazier Healthcare Partners has named David Topper as a senior advisor for its life sciences team.

Frazier Healthcare Partners has named David Topper as a senior advisor for its life sciences team. Topper is a former co-head of equity capital markets at JP Morgan.


MENLO PARK, Calif.–(BUSINESS WIRE)–Frazier Healthcare Partners announced David Topper has joined the Life Sciences team as a Senior Advisor. He has over 35 years of experience in the capital markets.
Mr. Topper was formerly the global head of capital markets at a major growth equity investment firm.

Prior to that, he was Co-Head of Equity Capital Markets at J.P. Morgan, where he led the firm’s major advisory and capital-raising transactions and worked with the U.S. Treasury and other regulatory agencies on crisis-related issues. He also served as Chairman of the Commitments Committee at J.P. Morgan. Prior to this, Mr. Topper spent 22 years at Morgan Stanley where he served as Co-Head of U.S. Equity Capital Markets, Managing Director, and Chairman of the Equity Commitment Committee. Earlier in his career, he held several other senior management positions in Morgan Stanley’s Debt Capital Markets, Leveraged Finance, and Mergers & Acquisitions divisions.

“We are thrilled to have an accomplished public investor and capital markets professional like David join us,” said Patrick Heron, Managing Partner on the Frazier Life Sciences team. “His considerable experience in the capital markets will be very valuable in helping us identify attractive public opportunities in which to invest and introduce our portfolio companies to the IPO market.”

The Frazier Life Sciences team has been investing in public companies since 2005. Recent public investments include ARMO Biosciences (acquired by Eli Lilly), Ignyta (acquired by Roche), Iovance Therapeutics (NASDAQ: IOVA), and Krystal Biotech (NASDAQ: KRYS).

About Frazier Healthcare Partners
Founded in 1991, Frazier Healthcare Partners is a leading provider of growth and venture capital to healthcare companies. With nearly $4.8 billion total capital raised, Frazier has invested in over 200 companies, with investment types ranging from company creation and venture capital to buyouts of profitable lower-middle market companies. The firm’s Growth Buyout team invests in healthcare and pharmaceutical services, medical products and related sectors. The Life Sciences team invests in therapeutics and related areas that are addressing unmet medical needs through innovation. Frazier has offices in Seattle, WA, and Menlo Park, CA, and invests broadly across the U.S., Canada and Europe.

For more information about Frazier Healthcare Partners, visit the company’s website at